Navigation Links
Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
Date:11/18/2009

RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely disclosed on the internet.

Data were presented in a student course at the University of Pennsylvania School of Medicine from a single subject treated with SB-728-T who, as part of the study, began a structured treatment interruption (STI) from his antiviral drug therapy four weeks after SB-728-T treatment. This subject was reported to have stable CD4+ and ZFN-modified T-cell levels and an undetectable viral load one month post STI initiation. Previous studies have shown that in subjects undergoing an STI, the average time to detection of an increase in viral load is two to four weeks. While this subject continues to demonstrate stable CD4+ T-cell counts and stable levels of ZFN-modified T-cells, by six weeks post STI initiation the subject had a detectable viral load.

As previously stated, the company and the University of Pennsylvania intend to provide updates on the two ongoing Phase 1 SB-728-T trials only at appropriate scientific or medical meetings.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused o
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
2. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
3. Sangamo Announces Pricing of Public Offering of Common Stock
4. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
5. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
6. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
7. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
8. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
10. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
11. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
(Date:7/10/2014)... Senior supply chain management executives from over 50 ... of “Reducing Cost, Lead Time, & Defects in the ... the partnership of the Bio Supply Management Alliance ( ... SCMI) of the University of San Diego in ... Institute of Peace and Justice in San Diego, Devendra ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... Quantitative Research ... Worldwide, NEW YORK, ... of those fielded in the US and abroad -- were,conducted online last ... report, released today, indicates that Internet-based market,research -- once the orphan of ...
... Inc.,(Scimitar) issues a review of Neurobiological Technologies, Inc. ... at One Stroke,Drug at a Time; Each One ... our website: http://www.scimitarequity.com ., Neurobiological Technologies, ... business of acquiring and developing central nervous system,related ...
... Mark Ahn Brings ZyGEM Extensive Expertise in Developing and ... Commercializing Novel Clinical Products--, SOLANA BEACH, ... unique and innovative enzymatic solutions for DNA,extraction and detection and ... Ahn, Ph.D., as Chair of its newly,formed Clinical Advisory Board. ...
Cached Biology Technology:Technology Transforms Market Research in Pharmaceutical Industry 2Technology Transforms Market Research in Pharmaceutical Industry 3Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc. 2ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board 2ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board 3
(Date:7/10/2014)... organization of the International Science and Business Belt project ... researchers, led by professor Won Do Heo, have developed ... can remotely control specific receptors by light. They have ... with neuronal differentiation inducement. , The most significant feature ... to activate neuronal functions without the need of other ...
(Date:7/10/2014)... even improve the state of fisheries resources in ... Mediterranean has deteriorated over the past 20 years. ... reported in the Cell Press journal Current ... stringent monitoring of Mediterranean fishing activities, better enforcement ... Mediterranean waters. , Their data show that the ...
(Date:7/10/2014)... Institute for Interdisciplinary Research (MIIR) and the Marshall ... announced they will be partnering with an international ... Under the agreement with Shanghai-based HD Biosciences Co. ... and risks of discovery and development of these ... intellectual property and commercialization rights to products developed ...
Breaking Biology News(10 mins):New optogenetic tool for controlling neuronal signalling by blue light 2Mediterranean fish stocks show steady decline 2Marshall University to partner with international company in drug development venture 2
... (November 4, 2009) For more than 25 years, ... ( Strombus gigas ) have been unsuccessfuluntil now. For ... produce beaded (nucleated) and non-beaded cultured pearls from the ... Atlantic University,s Harbor Branch Oceanographic Institute (HBOI). With less ...
... vegetables is a new, patented technology in which a low-energy ... information on produce, thereby eliminating the need for common sticker-type ... variety of fruits and vegetables and is being used in ... been approved in Asia, South Africa, Central and South America, ...
... Researchers from the UCLA Henry Samueli School of ... successfully reconstituted in the laboratory the enzyme responsible for ... The research, published Oct. 23 in the journal ... of other compounds with similarly beneficial effects. ...
Cached Biology News:Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3Laser etching safe alternative for labeling grapefruit 2UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin 2
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
RABBIT ANTI D-TYROSINE CONJUGATE...
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: